Today: May 22, 2025
RU / EN
Last update: Apr 30, 2025
Home page → All issues → Volume 8, Issue 1 (2016) → Article details
Drug Allergic Reactions: Current Views (Review)

Drug Allergic Reactions: Current Views (Review)

Eliseeva T.I., Balabolkin I.I.
Key words: drug allergy; diagnosing drug allergy; drug hypersensitivity reactions.
2016, volume 8, issue 1, page 159.
DOI: https://doi.org/10.17691/stm2016.8.1.22

Full text

html pdf
13491
3697

More than 7% of population suffer from drug allergy. Cases of heavy life-threatening allergic reactions are well known. In this review current considerations of mechanisms of drug immune hypersensitivity development are presented, the main clinical forms and methods basophil activation, reactions of leucocyte blast transformation, quantitative determination of cytokines and other proteins, e.g. granzyme and tryptase in peripheral blood). However, not all of these methods are available in real clinical practice, the list of commercial kits for diagnosis of drug allergy is limited. Therefore, it is especially important in patient management to rely on history-taking and general clinical examination data, to consider the available information on association of drug allergy and infections caused by viruses of herpes-group, especially in children population, on hereditary predisposition to some kinds of drug allergy.

  1. Demoly P., Adkinson N.F., Brockow K., Castells M., Chiriac A.M., Greenberger P.A., Khan D.A., Lang D.M., Park H.S., Pichler W., Sanchez-Borges M., Shiohara T., Thong B.Y. International Consensus on drug allergy. Allergy 2014; 69(4): 420–437, http://dx.doi.org/10.1111/all.12350.
  2. Gomes E., Cardoso M.F., Praca F., Gomes L., Marino E., Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 2004; 34(10): 1597–1601, http://dx.doi.org/10.1111/j.1365-2222.2004.02070.x.
  3. Dao R.-L., Su S.-C., Chung W.-H. Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms. Asia Pac Allergy 2015; 5(2): 59–67, http://dx.doi.org/10.5415/apallergy.2015.5.2.59.
  4. Balabolkin I.I., Bulgakova V.A. Klinicheskaya allergologiya detskogo vozrasta s neotlozhnymi sostoyaniyami [Clinical allergology of childhood with urgent conditions]. Moscow: MIA; 2011; 264 p.
  5. Rawlins M.D., Thompson J.W. Mechanisms of adverse drug reactions. In: Textbook of adverse drug reactions. Davies D.M. (editor). Oxford: Oxford University Press; 1991; p. 18–45.
  6. Doña I., Barrionuevo E., Blanca-Lopez N., Torres M.J., Fernandez T.D., Mayorga C., Canto G., Blanca M. Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J Investig Allergol Clin Immunol 2014; 24(3): 143–153.
  7. Smyth R.M.D., Gargon E., Kirkham J., Cresswell L., Golder S., Smyth R., Williamson P. Adverse drug reactions in children — a systematic review. PLoS One 2012; 7(3): e24061, http://dx.doi.org/10.1371/journal.pone.0024061.
  8. Ponvert C., Scheinmann P. Allergic and pseudoallergic reactions to analgesics, antipyretics and non-steroidal anti-inflammatory drugs. Arch Pediatr 2007; 14(5): 507–512, http://dx.doi.org/10.1016/j.arcped.2007.03.009.
  9. Ayuso P., Blanca-López N., Doña I., Torres M.J., Guéant-Rodríguez R.M., Canto G., Sanak M., Mayorga C., Guéant J.L., Blanca M., Cornejo-García J.A. Advanced phenotyping in hypersensitivity drug reactions to NSAIDs. Clin Exp Allergy 2013; 43(10): 1097–1109, http://dx.doi.org/10.1111/cea.12140.
  10. Farnam K., Chang C., Teuber S., Gershwin M.E. Nonallergic drug hypersensitivity reactions. Int Arch Allergy Immunol 2012; 159(4): 327–345, http://dx.doi.org/10.1159/000339690.
  11. Newmark J.L., Mehra A., Singla A.K. Radiocontrast media allergic reactions and interventional pain practice — a review. Pain Physician 2012; 15(5): E665–E675.
  12. Grigiene G., Norkūnienė J., Kvedariene V. The time delay between drug intake and bronchospasm for nonsteroidal antiinflammatory drugs sensitive patients. World Allergy Organ J 2010; 3(12): 266–270, http://dx.doi.org/10.1097/wox.0b013e3181fdfc5f.
  13. Stone S.F., Phillips E.J., Wiese M.D., Heddle R.J., Brown S.G. Immediate-type hypersensitivity drug reactions. Br J Clin Pharmacol 2014; 78(1): 1–13, http://dx.doi.org/10.1111/bcp.12297.
  14. Erkoçoğlu M., Kaya A., Civelek E., Ozcan C., Cakır B., Akan A., Toyran M., Ginis T., Kocabas C.N. Prevalence of confirmed immediate type drug hypersensitivity reactions among school children. Pediatr Allergy Immunol 2013; 24(2): 160–167, http://dx.doi.org/10.1111/pai.12047.
  15. Schrijvers R., Gilissen L., Chiriac A.M., Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy 2015; 5: 31, http://dx.doi.org/10.1186/s13601-015-0073-8.
  16. Yazıcıoğlu M. Approach to drug allergies in the childhood. Turk Pediatri Ars 2014; 49(2): 99–103, http://dx.doi.org/10.5152/tpa.2014.1944.
  17. Blanca M., Romano A., Torres M.J., Férnandez J., Mayorga C., Rodriguez J., Demoly P., Bousquet P.J., Merk H.F., Sanz M.L., Ott H., Atanasković-Marković M. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64(2): 183–193, http://dx.doi.org/10.1111/j.1398-9995.2008.01916.x.
  18. Bircher A.J., Scherer Hofmeier K. Drug hypersensitivity reactions: Inconsistency in the use of the classification of immediate and nonimmediate reactions. J Allergy Clin Immunol 2012; 129(1): 263–264, http://dx.doi.org/10.1016/j.jaci.2011.08.042.
  19. Pichler W.J., Adam J., Daubner B., Gentinetta T., Keller M., Yerly D. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am 2010; 94(4): 645–664, http://dx.doi.org/10.1016/j.mcna.2010.04.003.
  20. Gómez E., Torres M.J., Mayorga C., Blanca M. Immunologic evaluation of drug allergy. Allergy Asthma Immunol Res 2012; 4(5): 251–263, http://dx.doi.org/10.4168/aair.2012.4.5.251.
  21. Gell P.G.H., Coombs R.R.A. The classification of allergic reactions underlying disease. In: Clinical aspects of immunology. Coombs R.R.A., Gell P.G.H. (editors). London, UK: Blackwell Sci; 1963; p. 317–337.
  22. Pichler W.J. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139(8): 683–693, http://dx.doi.org/10.7326/0003-4819-139-8-200310210-00012.
  23. Park B.K., Naisbitt D.J., Demoly P. Drug hypersensitivity. In: Allergy. New York: Elsevier BV; 2012; p. 321–330, http://dx.doi.org/10.1016/b978-0-7234-3658-4.00020-2.
  24. Macy E. Practical management of patients with a history of immediate hypersensitivity to common non-beta-lactam drugs. Curr Allergy Asthma Rep 2016; 16(1): 4, http://dx.doi.org/10.1007/s11882-015-0584-3.
  25. Limsuwan T., Demoly P. Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock). Med Clin North Am 2010; 94(4): 691–710, http://dx.doi.org/10.1016/j.mcna.2010.03.007.
  26. Eliseeva T.I. Neotlozhnaya allergologiya. V kn.: Neotlozhnye sostoyaniya v pediatrii [Urgent allergology. In: Urgent conditions in pediatrics]. Pod red. Prakhova A.V. [Prakhov A.V. (editor)]. Nizhny Novgorod: Izdatel'stvo NGMA; 2005; p. 191–213.
  27. Leach M.W., Rottman J.B., Hock M.B., Finco D., Rojko J.L., Beyer J.C. Immunogenicity/hypersensitivity of biologics. Toxicol Pathol 2014; 42(1): 293–300, http://dx.doi.org/10.1177/0192623313510987.
  28. Garratty G. Immune hemolytic anemia caused by drugs. Expert Opin Drug Saf 2012; 11(4): 635–642, http://dx.doi.org/10.1517/14740338.2012.678832.
  29. Rojko J.L., Evans M.G., Price S.A., Han B., Waine G., DeWitte M., Haynes J., Freimark B., Martin P., Raymond J.T., Evering W., Rebelatto M.C., Schenck E., Horvath C. Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies. Toxicol Pathol 2014; 42(4): 725–764, http://dx.doi.org/10.1177/0192623314526475.
  30. Clark B.M., Kotti G.H., Shah A.D., Conger N.G. Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy 2006; 26(5): 705–708, http://dx.doi.org/10.1592/phco.26.5.705.
  31. Koransky R., Ferastraoaru D., Jerschow E. Single nonsteroidal anti-inflammatory drug induced serum sickness-like reaction to naproxen in a patient able to tolerate both aspirin and ibuprofen. J Allergy Clin Immunol Pract 2016; 4(1): 160–161, http://dx.doi.org/10.1016/j.jaip.2015.07.019.
  32. Hanai S., Sato T., Takeda K., Nagatani K., Iwamoto M., Minota S. Drug-induced lupus caused by long term minocycline treatment for acne vulgaris. Arerugi 2015; 64(9): 1269–1273, http://dx.doi.org/10.15036/arerugi.64.1269.
  33. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009; 7(2): 142–160, http://dx.doi.org/10.1111/j.1610-0387.2008.06878.x.
  34. Bircher A.J., Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North Am 2010; 94(4): 711–725, http://dx.doi.org/10.1016/j.mcna.2010.04.001.
  35. Ghane Shahrbaf F., Assadi F. Drug-induced renal disorders. J Renal Inj Prev 2015; 4(3): 57–60, http://dx.doi.org/10.12861/jrip.2015.12.
  36. Schwaiblmair M., Behr W., Haeckel T., Märkl B., Foerg W., Berghaus T. Drug induced interstitial lung disease. Open Respir Med J 2012; 6: 63–74, http://dx.doi.org/10.2174/1874306401206010063.
  37. Jacquier J., Chik C.L., Senior P.A. A practical, clinical approach to the assessment and management of suspected insulin allergy. Diabet Med 2013; 30(8): 977–985, http://dx.doi.org/10.1111/dme.12194.
  38. Hoffman A.G., Schram S.E., Ercan-Fang N.G., Warshaw E.M. Type I allergy to insulin: case report and review of localized and systemic reactions to insulin. Dermatitis 2008; 19(1): 52–58.
  39. Kim D., Baraniuk J. Delayed-type hypersensitivity reaction to the meta-cresol component of insulin. Ann Allergy Asthma Immunol 2007; 99(2): 194–195, http://dx.doi.org/10.1016/S1081-1206(10)60645-X.
  40. Faulkner L., Meng X., Park B.K., Naisbitt D.J. The importance of hapten-protein complex formation in the development of drug allergy. Curr Opin Allergy Clin Immunol 2014; 14(4): 293–300, http://dx.doi.org/10.1097/ACI.0000000000000078.
  41. Oussalah A., Mayorga C., Blanca M., Barbaud A., Nakonechna A., Cernadas J., Gotua M., Brockow K., Caubet J.C., Bircher A., Atanaskovic M., Demoly P., Kase-Tanno L., Terreehorst I., Laguna J.J., Romano A., Guéant J.L.; Task force “Genetic predictors of drug hypersensitivity” of the European Network on Drug Allergy (ENDA) of EAACI. Genetic variants associated with drugs-induced immediate hypersensitivity reactions: a PRISMA-compliant systematic review. Allergy 2015, http://dx.doi.org/10.1111/all.12821 [Epub ahead of print].
  42. Pirmohamed M., Ostrov D.A., Park B.K. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J Allergy Clin Immunol 2015; 136(2): 236–244, http://dx.doi.org/10.1016/j.jaci.2015.06.022.
  43. Chung W.H., Hung S.I., Hong H.S., Hsih M.S., Yang L.C., Ho H.C., Wu J.Y., Chen Y.T. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 2004; 428(6982): 486, http://dx.doi.org/10.1038/428486a.
  44. Guglielmi L., Fontaine C., Gougat C., Avinens O., Eliaou J.F., Guglielmi P., Demoly P. IL-10 promoter and IL4-Ralpha gene SNPs are associated with immediate beta-lactam allergy in atopic women. Allergy 2006; 61(8): 921–927, http://dx.doi.org/10.1111/j.1398-9995.2006.01067.x.
  45. Caubet J.C., Kaiser L., Lemaître B., Fellay B., Gervaix A., Eigenmann P.A. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol 2011; 127(1): 218–222, http://dx.doi.org/10.1016/j.jaci.2010.08.025.
  46. Hubiche T., Milpied B., Cazeau C., Taïeb A., Léauté-Labrèze C. Association of immunologically confirmed delayed drug reaction and human herpesvirus 6 viremia in a pediatric case of drug-induced hypersensitivity syndrome. Dermatology 2011; 222(2): 140–141, http://dx.doi.org/10.1159/000324506.
  47. Özcan D., Seçkin D., Bilezikçi B., Arslan H. The role of human herpesvirus-6, Epstein–Barr virus and cytomegalovirus infections in the etiopathogenesis of different types of cutaneous drug reactions. Int J Dermatol 2010; 49(11): 1250–1254, http://dx.doi.org/10.1111/j.1365-4632.2010.04531.x.
  48. Camous X., Calbo S., Picard D., Musette P. Drug reaction with eosinophilia and systemic symptoms: an update on pathogenesis. Curr Opin Immunol 2012; 24(6): 730–735, http://dx.doi.org/10.1016/j.coi.2012.07.010.
  49. Balabolkin I.I. Drug allergy in children: clinical and pathogenetic types, diagnosis and prevention. Rossiyskiy pediatricheskiy zhurnal 2011; 1: 49–53.
  50. Ferrusquía J., Pérez-Martínez I., Gómez de la Torre R., Fernández-Almira M.L., de Francisco R., Rodrigo L., Riestra S. Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity. World J Gastroenterol 2015; 21(13): 4069–4077, http://dx.doi.org/10.3748/wjg.v21.i13.4069.
  51. Rossiyskaya assotsiatsiya allergologov i klinicheskikh immunologov. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniyu lekarstvennoy allergii [Russian Association of Allergology and Clinical Immunology. Federal guidelines for the diagnosis and treatment of drug allergy]. Moscow; 2014.
  52. Marzano A.V., Borghi A., Cugno M. Adverse drug reactions and organ damage: the skin. Eur J Intern Med 2016; 28: 17–24, http://dx.doi.org/10.1016/j.ejim.2015.11.017.
  53. Uetrecht J., Naisbitt D.J. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 2013; 65(2): 779–808, http://dx.doi.org/10.1124/pr.113.007450.
  54. Żukiewicz-Sobczak W.A., Wróblewska P., Adamczuk P., Zwoliński J., Oniszczuk A., Wojtyła-Buciora P., Silny W. Drugs as important factors causing allergies. Postepy Dermatol Alergol 2015; 32(5): 388–392, http://dx.doi.org/10.5114/pdia.2014.44021.
  55. Valeyrie-Allanore L., Sassolas B., Roujeau J.C. Drug-induced skin, nail and hair disorders. Drug Saf 2007; 30(11): 1011–1030, http://dx.doi.org/10.2165/00002018-200730110-00003.
  56. Segal A.R., Doherty K.M., Leggott J., Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics 2007; 120(4): e1082–e1096, http://dx.doi.org/10.1542/peds.2005-2321.
  57. Kowalski M.L., Woessner K., Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol 2015; 136(2): 245–251, http://dx.doi.org/10.1016/j.jaci.2015.06.021.
  58. Rossiyskaya assotsiatsiya allergologov i klinicheskikh immunologov. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniyu krapivnitsy [Russian Association of Allergology and Clinical Immunology. Federal guidelines for the diagnosis and treatment of urticaria]. Moscow; 2013.
  59. Flowers H., Brodell R., Brents M., Wyatt J.P. Fixed drug eruptions: presentation, diagnosis, and management. South Med J 2014; 107(11): 724–727, http://dx.doi.org/10.14423/SMJ.0000000000000195.
  60. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9(4): 316–321, http://dx.doi.org/10.1097/ACI.0b013e32832cda4c.
  61. Sidoroff A., Halevy S., Bavinck J.N., Vaillant L., Roujeau J.C. Acute generalized exanthematous pustulosis (AGEP) — a clinical reaction pattern. J Cutan Pathol 2001; 28(3): 113–119, http://dx.doi.org/10.1034/j.1600-0560.2001.028003113.x.
  62. Pavlos R., Mallal S., Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012; 13(11): 1285–1306, http://dx.doi.org/10.2217/pgs.12.108.
  63. Shear N.H., Spielberg S.P. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82(6): 1826–1832, http://dx.doi.org/10.1172/JCI113798.
  64. Walsh S.A., Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol 2011; 36(1): 6–11, http://dx.doi.org/10.1111/j.1365-2230.2010.03967.x.
  65. Cacoub P., Musette P., Descamps V., Meyer O., Speirs C., Finzi L., Roujeau J.C. The DRESS syndrome: a literature review. Am J Med 2011; 124(7): 588–597, http://dx.doi.org/10.1016/j.amjmed.2011.01.017.
  66. Picard D., Janela B., Descamps V., D’Incan M., Courville P., Jacquot S., Rogez S., Mardivirin L., Moins-Teisserenc H., Toubert A., Benichou J., Joly P., Musette P. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010; 2(46): 46–62, http://dx.doi.org/10.1126/scitranslmed.3001116.
  67. Lamoreux M.R., Sternbach M.R., Hsu W.T. Erythema multiforme. Am Fam Physician 2006; 74(11): 1883–1888.
  68. Eun L.Y., Go J.W., Kang W.H., Kim S.H., Cho H.K. Erythema multiforme associated with Kawasaki Disease in a Korean child. Eur J Dermatol 2010; 20(4): 524–525, http://dx.doi.org/10.1684/ejd.2010.0972.
  69. Beckwith H. Erythema multiforme: a simple rash or sinister sign? BMJ Case Rep 2012; 2012: bcr1120115072, http://dx.doi.org/10.1136/bcr.11.2011.5072.
  70. Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Soyuz pediatrov Rossii. Federal'nye klinicheskie rekomendatsii po okazaniyu meditsinskoy pomoshchi detyam s mnogoformnoy ekssudativnoy eritemoy i toksikodermiey [Ministry of Health of the Russian Federation. Union of Pediatricians of Russia. Federal guidelines for the provision of medical care for children with erythema multiforme and toxicodermie]. Moscow; 2015.
  71. Chang Y.S., Huang F.C., Tseng S.H., Hsu C.K., Ho C.L., Sheu H.M. Erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007; 26(2): 123–129, http://dx.doi.org/10.1097/ico.0b013e31802eb264.
  72. Łoboda J., Dudzik A., Chomyszyn-Gajewska M. Stevens-Johnson syndrom and toxic epidermal necrolysis — based on literature. Przegl Lek 2015; 72(1): 35–37.
  73. Wheatley L.M., Plaut M., Schwaninger J.M., Banerji A., Castells M., Finkelman F.D., Gleich G.J., Guttman-Yassky E., Mallal S.A., Naisbitt D.J., Ostrov D.A., Phillips E.J., Pichler W.J., Platts-Mills T.A., Roujeau J.C., Schwartz L.B., Trepanier L.A. Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. J Allergy Clin Immunol 2015; 136(2): 262–271.e2, http://dx.doi.org/10.1016/j.jaci.2015.05.027.
  74. Harr T., French L.E. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphanet J Rare Dis 2010; 5: 39, http://dx.doi.org/10.1186/1750-1172-5-39.
  75. Roujeau J.C. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209(2): 123–129, http://dx.doi.org/10.1016/j.tox.2004.12.022.
  76. Wei C.Y., Chung W.H., Huang H.W., Chen Y.T., Hung S.I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012; 129(6): 1562–1569.e5, http://dx.doi.org/10.1016/j.jaci.2011.12.990.
  77. Chung W.H., Hung S.I., Yang J.Y., Su S.C., Huang S.P., Wei C.Y., Chin S.W., Chiou C.C., Chu S.C., Ho H.C., Yang C.H., Lu C.F., Wu J.Y., Liao Y.D., Chen Y.T. Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14(12): 1343–1350, http://dx.doi.org/10.1038/nm.1884.
  78. de Araujo E., Dessirier V., Laprée G., Valeyrie-Allanore L., Ortonne N., Stathopoulos E.N., Bagot M., Bensussan A., Mockenhaupt M., Roujeau J.C., Tsapis A. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol 2011; 20(2): 107–112, http://dx.doi.org/10.1111/j.1600-0625.2010.01176.x.
  79. Abe R., Yoshioka N., Murata J., Fujita Y., Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 2009; 151(7): 514–515, http://dx.doi.org/10.7326/0003-4819-151-7-200910060-00016.
  80. Rodríguez-Pazos L., Gómez-Bernal S., Rodríguez-Granados M.T., Toribio J. Photodistributed erythema multiforme. Actas Dermosifiliogr 2013; 104(8): 645–653, http://dx.doi.org/10.1016/j.adengl.2012.01.024.
  81. Rossiyskaya assotsiatsiya allergologov i klinicheskikh immunologov. Federal'nye klinicheskie rekomendatsii po anafilakticheskomu shoku [Russian Association of Allergology and Clinical Immunology. Federal guidelines for the anaphylactic shock]. Moscow; 2013.
  82. Simons F.E., Ardusso L.R., Bilò M.B., Cardona V., Ebisawa M., El-Gamal Y.M., Lieberman P., Lockey R.F., Muraro A., Roberts G., Sanchez-Borges M., Sheikh A., Shek L.P., Wallace D.V., Worm M. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014; 7(1): 9, http://dx.doi.org/10.1186/1939-4551-7-9.
  83. Simons F.E., Ebisawa M., Sanchez-Borges M., Thong B.Y., Worm M., Tanno L.K., Lockey R.F., El-Gamal Y.M., Brown S.G., Park H.S., Sheikh A. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J 2015; 8(1): 32, http://dx.doi.org/10.1186/s40413-015-0080-1.
  84. Mori F., Fili L., Barni S., Sarti L., Pucci N., Parronchi P., Novembre E. Drug fever after a single dose of amoxicillin-clavulanic acid. J Allergy Clin Immunol Pract 2015, http://dx.doi.org/10.1016/j.jaip.2015.11.030 [Epub ahead of print].
  85. Patel R.A., Gallagher J.C. Drug fever. Pharmacotherapy 2010; 30(1): 57–69, http://dx.doi.org/10.1592/phco.30.1.57.
  86. Gomes E.R., Brockow K., Kuyucu S., Saretta F., Mori F., Blanca-Lopez N., Ott H., Atanaskovic-Markovic M., Kidon M., Caubet J.C., Terreehorst I.; ENDA/EAACI Drug Allergy Interest Group. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy 2016; 71(2): 149–161, http://dx.doi.org/10.1111/all.12774.
  87. Shiohara T., Kano Y. A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol 2007; 33(1): 124–133, http://dx.doi.org/10.1007/s12016-007-8010-9.
  88. Chovel-Sella A., Ben Tov A., Lahav E., Mor O., Rudich H., Paret G., Reif S. Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics 2013; 131(5): e1424–e1427, http://dx.doi.org/10.1542/peds.2012-1575.
  89. Leuppi J.D., Schnyder P., Hartmann K., Reinhart W.H., Kuhn M. Drug-induced bronchospasm: analysis of 187 spontaneously reported cases. Respiration 2001; 68(4): 345–351, http://dx.doi.org/10.1159/000050525.
  90. Hompes S., Köhli A., Nemat K., Scherer K., Lange L., Rueff F., Rietschel E., Reese T., Szepfalusi Z., Schwerk N., Beyer K., Hawranek T., Niggemann B., Worm M. Provoking allergens and treatment of anaphylaxis in children and adolescents — data from the anaphylaxis registry of German-speaking countries. Pediatr Allergy Immunol 2011; 22(6): 568–574, http://dx.doi.org/10.1111/j.1399-3038.2011.01154.x.
  91. Levi N., Bastuji-Garin S., Mockenhaupt M., Roujeau J.C., Flahault A., Kelly J.P., Martin E., Kaufman D.W., Maison P. Medications as risk factors of Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009; 123(2): e297–e304, http://dx.doi.org/10.1542/peds.2008-1923.
  92. Rive C.M., Bourke J., Phillips E.J. Testing for drug hypersensitivity syndromes. Clin Biochem Rev 2013; 34(1): 15–38.
  93. Brockow K., Przybilla B., Aberer W., Bircher A.J., Brehler R., Dickel H., Fuchs T., Jakob T., Lange L., Pfützner W., Mockenhaupt M., Ott H., Pfaar O., Ring J., Sachs B., Sitter H., Trautmann A., Treudler R., Wedi B., Worm M., Wurpts G., Zuberbier T., Merk H.F. Guideline for the diagnosis of drug hypersensitivity reactions. Allergo J Int 2015; 24(3): 94–105, http://dx.doi.org/10.1007/s40629-015-0052-6.
  94. Chiriac A.M., Demoly P. Multiple drug hypersensitivity syndrome. Curr Opin Allergy Clin Immunol 2013; 13(4): 323–329, http://dx.doi.org/10.1097/aci.0b013e3283630c36.
  95. Neukomm C.B., Yawalkar N., Helbling A., Pichler W.J. T-cell reactions to drugs in distinct clinical manifestations of drug allergy. J Investig Allergol Clin Immunol 2001; 11(4): 275–284.
  96. Macy E., Ho N.J. Multiple drug intolerance syndrome: prevalence, clinical characteristics, and management. Ann Allergy Asthma Immunol 2012; 108(2): 88–93, http://dx.doi.org/10.1016/j.anai.2011.11.006.
  97. Asero R. Multiple drug allergy syndrome: a distinct clinical entity. Curr Allergy Rep 2001; 1(1): 18–22, http://dx.doi.org/10.1007/s11882-001-0092-5.
  98. Omer H.M., Hodson J., Thomas S.K., Coleman J.J. Multiple drug intolerance syndrome: a large-scale retrospective study. Drug Saf 2014; 37(12): 1037–1045, http://dx.doi.org/10.1007/s40264-014-0236-x.
  99. Hari Y., Frutig-Schnyder K., Hurni M., Yawalkar N., Zanni M.P., Schnyder B., Kappeler A., von Greyerz S., Braathen L.R., Pichler W.J. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001; 31(9): 1398–1408, http://dx.doi.org/10.1046/j.1365-2222.2001.01164.x.
  100. Bircher A.J. Symptoms and danger signs in acute drug hypersensitivity. Toxicology 2005; 209(2): 201–207, http://dx.doi.org/10.1016/j.tox.2004.12.036.
  101. Lee A.Y., Chey W.Y., Choi J., Jeon J.S. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol 2002; 82(2): 114–117, http://dx.doi.org/10.1080/00015550252948149.
  102. Kränke B., Aberer W. Skin testing for IgE-mediated drug allergy. Immunol Allergy Clin North Am 2009; 29(3): 503–516, http://dx.doi.org/10.1016/j.iac.2009.04.003.
  103. Brockow K., Garvey L.H., Aberer W., Atanaskovic-Markovic M., Barbaud A., Bilo M.B., Bircher A., Blanca M., Bonadonna B., Campi P., Castro E., Cernadas J.R., Chiriac A.M., Demoly P., Grosber M., Gooi J., Lombardo C., Mertes P.M., Mosbech H., Nasser S., Pagani M., Ring J., Romano A., Scherer K., Schnyder B., Testi S., Torres M., Trautmann A., Terreehorst I.; ENDA/EAACI Drug Allergy Interest Group. Skin test concentrations for systemically administered drugs — an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68(6): 702–712, http://dx.doi.org/10.1111/all.12142.
  104. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005; 209(2): 209–216, http://dx.doi.org/10.1016/j.tox.2004.12.024.
  105. Santiago F., Gonçalo M., Vieira R., Coelho S., Figueiredo A. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis 2010; 62(1): 47–53, http://dx.doi.org/10.1111/j.1600-0536.2009.01659.x.
  106. Rerkpattanapipat T., Chiriac A.M., Demoly P. Drug provocation tests in hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2011; 11(4): 299–304, http://dx.doi.org/10.1097/ACI.0b013e328348a4e9.
  107. Bousquet P.J., Gaeta F., Bousquet-Rouanet L., Lefrant J.Y., Demoly P., Romano A. Provocation tests in diagnosing drug hypersensitivity. Curr Pharm Des 2008; 14(27): 2792–2802, http://dx.doi.org/10.2174/138161208786369731.
  108. Aberer W., Bircher A., Romano A., Blanca M., Campi P., Fernandez J., Brockow K., Pichler W.J., Demoly P.; European Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58(9): 854–863, http://dx.doi.org/10.1034/j.1398-9995.2003.00279.x.
  109. Mayorga C., Sanz M.L., Gamboa P., Garcia-Aviles M.C., Fernandez J., Torres M.J.; Spanish Society of Allergy and Clinical; Immunology; Immunology and Drug Allergy Committee. In vitro methods for diagnosing nonimmediate hypersensitivity reactions to drugs. J Investig Allergol Clin Immunol 2013; 23(4): 213–225.
  110. Fontaine C., Mayorga C., Bousquet P.J., Arnoux B., Torres M.J., Blanca M., Demoly P. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy 2007; 62(1): 47–52, http://dx.doi.org/10.1111/j.1398-9995.2006.01268.x.
  111. Demoly P., Lebel B., Messaad D., Sahla H., Rongier M., Daurès J.P., Godard P., Bousquet J. Predictive capacity of histamine release for the diagnosis of drug allergy. Allergy 1999; 54(5): 500–506, http://dx.doi.org/10.1034/j.1398-9995.1999.00020.x.
  112. Lebel B., Messaad D., Kvedariene V., Rongier M., Bousquet J., Demoly P. Cysteinyl-leukotriene release test (CAST) in the diagnosis of immediate drug reactions. Allergy 2001; 56(7): 688–692, http://dx.doi.org/10.1034/j.1398-9995.2001.00103.x.
  113. Mirone C., Preziosi D., Mascheri A., Micarelli G., Farioli L., Balossi L.G., Scibilia J., Schroeder J., Losappio L.M., Aversano M.G., Stafylaraki C., Nichelatti M., Pastorello E.A. Identification of risk factors of severe hypersensitivity reactions in general anaesthesia. Clin Mol Allergy 2015; 13(1): 11, http://dx.doi.org/10.1186/s12948-015-0017-9.
  114. Kvedariene V., Kamey S., Ryckwaert Y., Rongier M., Bousquet J., Demoly P., Arnoux B. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Allergy 2006; 61(3): 311–315, http://dx.doi.org/10.1111/j.1398-9995.2006.00978.x.
  115. Leysen J., Sabato V., Verweij M.M., De Knop K.J., Bridts C.H., De Clerck L.S., Ebo D.G. The basophil activation test in the diagnosis of immediate drug hypersensitivity. Expert Rev Clin Immunol 2011; 7(3): 349–355, http://dx.doi.org/10.1586/eci.11.14.
  116. Pineda F., Ariza A., Mayorga C., Arribas F., González-Mendiola R., Blanca-López N., Davila G., Cabañes N., Canto G., Laguna J.J., Senent C., Stahl-Skov P., Palacios R., Blanca M., Torres M.J. Role of histamine release test for the evaluation of patients with immediate hypersensitivity reactions to clavulanic acid. Int Arch Allergy Immunol 2016; 168(4): 233–240, http://dx.doi.org/10.1159/000443274.
  117. Hausmann O.V., Gentinetta T., Bridts C.H., Ebo D.G. The basophil activation test in immediate-type drug allergy. Immunol Allergy Clin North Am 2009; 29(3): 555–566, http://dx.doi.org/10.1016/j.iac.2009.04.011.
Eliseeva T.I., Balabolkin I.I. Drug Allergic Reactions: Current Views (Review). Sovremennye tehnologii v medicine 2016; 8(1): 159, https://doi.org/10.17691/stm2016.8.1.22


Journal in Databases

pubmed_logo.jpg

web_of_science.jpg

scopus.jpg

crossref.jpg

ebsco.jpg

embase.jpg

ulrich.jpg

cyberleninka.jpg

e-library.jpg

lan.jpg

ajd.jpg

SCImago Journal & Country Rank

Publication is registered by Federal Service for Supervision in the Sphere of Telecom, Information Technologies and Mass Communications.
Mass Media Registration Certificate PE № FS 77-79187 dated October 16, 2020.

If reproducing any part of the publication a reference to the Journal is obligatory.